Veralipride
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Agreal, Agradil |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.060.376 ![]() |
Chemical and physical data | |
Formula | C17H25N3O5S |
Molar mass | 383.46 g·mol−1 |
3D model (JSmol) | |
| |
InChI
| |
![]() ![]() |
Veralipride (Agreal, Agradil) is a benzamide neuroleptic medicine indicated in the treatment of vasomotor symptoms associated with the menopause.[1] It was first authorised for use in 1979. Veralipride has never gained approval in the United States.
In September 2006, it was withdrawn from the Spanish market. As a result, the European Commission referred the matter to the European Medicines Agency (EMA). On July 2007, the EMA recommended the withdrawal of marketing authorisations for veralipride.[2]
See also[]
- Typical antipsychotic
- Benzamide
References[]
- ^ Carranza-Lira S (September 2010). "Actual status of veralipride use". Clinical Interventions in Aging. 5: 271–6. doi:10.2147/cia.s12640. PMC 2938034. PMID 20852674.
- ^ "Overall Summary of the Scientific Evaluation of Medicinal Products Containing Veralipride" (PDF). EMEA.
Categories:
- Allyl compounds
- Benzamides
- Pyrrolidines
- Sulfonamides
- Withdrawn drugs
- Typical antipsychotics
- Nervous system drug stubs